Transient thyrotoxicosis during nivolumab treatment

Authors :: van Kooten, M. J.
van den Berg, G.
Glaudemans, A. W. J. M.
Hiltermann, T. J. N.
Groen, H. J. M.
Rutgers, A.
Links, T. P.
Translational Immunology Groningen (TRIGR)
Damage and Repair in Cancer Development and Cancer Treatment (DARE)
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
Source :: The Netherlands Journal of Medicine, 75(5), 204-207. van Zuiden Communications BV.
Publication Year :: 2017
Abstract: Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.

Subjects :: DOCETAXEL
lung cancer
ADVANCED MELANOMA
CELL LUNG-CANCER
Checkpoint inhibition
thyroiditis
thyrotoxicosis
immune related adverse reactions
IMMUNE CHECKPOINT INHIBITORS
PEMBROLIZUMAB
TOXICITIES

Language :: English
ISSN :: 03002977
Database :: OpenAIRE
Journal :: The Netherlands Journal of Medicine, 75(5), 204-207. van Zuiden Communications BV.
Accession number :: edsair.narcis........ba4b7ee4f24c499d0e2e8ac14e30e140

Tools